Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dabigatran, which is administered in a fixed dose and does not require laboratory monitoring, may be suitable for extended treatment of venous thromboembolism. METHODS: In two double-blind, randomized trials, we compared dabigatran at a dose of 150 mg twice daily with warfarin (active-control study) or with placebo (placebo-control study) in patients with venous thromboembolism who had completed at least 3 initial months of therapy. RESULTS: In the active-control study, recurrent venous thromboembolism occurred in 26 of 1430 patients in the dabigatran group (1.8%) and 18 of 1426 patients in the warfarin group (1.3%) (hazard ratio with dabigatran, 1.44; 95% confidence interval [CI], 0.78 to 2.64; P=0.01 for noninferiority). Major bleeding occurred in 13 patients in the dabigatran group (0.9%) and 25 patients in the warfarin group (1.8%) (hazard ratio, 0.52; 95% CI, 0.27 to 1.02). Major or clinically relevant bleeding was less frequent with dabigatran (hazard ratio, 0.54; 95% CI, 0.41 to 0.71). Acute coronary syndromes occurred in 13 patients in the dabigatran group (0.9%) and 3 patients in the warfarin group (0.2%) (P=0.02). In the placebo-control study, recurrent venous thromboembolism occurred in 3 of 681 patients in the dabigatran group (0.4%) and 37 of 662 patients in the placebo group (5.6%) (hazard ratio, 0.08; 95% CI, 0.02 to 0.25; P<0.001). Major bleeding occurred in 2 patients in the dabigatran group (0.3%) and 0 patients in the placebo group. Major or clinically relevant bleeding occurred in 36 patients in the dabigatran group (5.3%) and 12 patients in the placebo group (1.8%) (hazard ratio, 2.92; 95% CI, 1.52 to 5.60). Acute coronary syndromes occurred in 1 patient each in the dabigatran and placebo groups. CONCLUSIONS: Dabigatran was effective in the extended treatment of venous thromboembolism and carried a lower risk of major or clinically relevant bleeding than warfarin but a higher risk than placebo. (Funded by Boehringer Ingelheim; RE-MEDY and RE-SONATE ClinicalTrials.gov numbers, NCT00329238 and NCT00558259, respectively.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For patients who are treated with dabigatran for secondary prevention, only the standard regimen of 150 mg twice daily has been studied. 310”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [310]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Three DOACs have been studied for secondary prevention of recurrent VTE after completion of the primary treatment phase. 306,310,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [310]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Self-citationAntithrombotic Therapy for Venous Thromboembolic Disease
Hyers, T. M., Agnelli, G., Hull, R. D., Morris, T. A., Samama, M., Tapson, V., & Weg, J. G. (2001) · Chest · doi:10.1378/chest.119.1_suppl.176s · Cited by 2,042
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Self-citationKearon, C., Gent, M., Hirsh, J., Weitz, J., Kovacs, M. J., Anderson, D. R., Turpie, A. G., Green, D., Ginsberg, J. S., Wells, P., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,072
Self-citation(2003) · New England Journal of Medicine · doi:10.1056/nejmoa035451 · Cited by 887
Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035029 · Cited by 808
Self-citationKearon, C., Ginsberg, J. S., Kovacs, M. J., Anderson, D. R., Wells, P., Julian, J. A., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035422 · Cited by 751
Self-citationNewly identified events in the RE-LY trial
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Reilly, P. A., & Wallentin, L. (2010) · New England Journal of Medicine · doi:10.1056/nejmc1007378 · Cited by 688
Research works printed but not linked: 1
- 8. Cochrane Database Syst Rev 2000;3: CD001367.
Cited by
Items 101–200 of 1,000
Uresandi, F., Monréal, M., García-Bragado, F., Domenech, P., Lecumberri, R., Escribano, P., Zamorano, J. L., Jiménez, S., Ruiz‐Artacho, P., Lozano, F., et al. (2013) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2013.07.008 · Cited by 94
Treatment of Venous Thromboembolism With New Anticoagulant Agents
Becattini, C., & Agnelli, G. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.01.072 · Cited by 82
Salazar, C. A., del Aguila, D., & Cordova-Ramos, E. G. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009893.pub2 · Cited by 86
Adherence to long‐term anticoagulation treatment, what is known and what the future might hold
Bartoli-Abdou, J., Auyeung, V., Patel, J. P., & Arya, R. (2016) · British Journal of Haematology · doi:10.1111/bjh.14134 · Cited by 77
“Smaller studies have reported that greater than 85% of patients were adherent to dabigatran (Hu et al, 2015), with Schulman et al (2013b) showing a median adherence rate of 99 7% as calculated by medicine possession ratio (MPR).”
BackgroundCoons, J. C., Albert, L., Bejjani, A., & Iasella, C. J. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2369 · Cited by 76
Perzborn, E., Heitmeier, S., Buetehorn, U., & Laux, V. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12591 · Cited by 71
Alotaibi, G., Almodaimegh, H., McMurtry, M. S., & Wu, C. M. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2013.07.017 · Cited by 71
“1 Selection *** comparability * outcome ** RE-SONATE 2013 [10] 1353 Dabigatran Placebo 6 months after 618 months of anticoagulant VTE 56.”
BackgroundNovel Oral Anticoagulants in Patients With Renal Insufficiency: A Meta-analysis of Randomized Trials
Sardar, P., Chatterjee, S., Herzog, E., Nairooz, R. S., Mukherjee, D., & Halperin, J. L. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.04.015 · Cited by 70
New oral anticoagulants in elderly patients
Barco, S., Cheung, Y. W., Eikelboom, J. W., & Coppens, M. (2013) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2013.07.011 · Cited by 70
“Limited data on elderly patients is available for the RE-COVER and RE-MEDY trials through the online supplements of the main publications [23,24].”
BackgroundThe Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation
Antonucci, E., Poli, D., Tosetto, A., Pengo, V., Tripodi, A., Magrini, N., Marongiu, F., Palareti, G., & START-Register (2015) · PLoS ONE · doi:10.1371/journal.pone.0124719 · Cited by 71
“Several phase III, non-inferiority, large trials in patients with non-valvular atrial fibrillation (NVAF)[3–6], and studies of acute[7–11]or extended [12,13] treatment in patients with venous thromboembolism (VTE) have recently been published investigating the efficacy and safety of 4 different DOAC (dabigatran, rivar…”
BackgroundCaldeira, D., Barra, M., Ferreira, A., Rocha, A., Augusto, A., Pinto, F. J., Costa, J. N., & Ferreira, J. J. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13412 · Cited by 73
The use of direct oral anticoagulants in inherited thrombophilia
Skelley, J. W., White, C. W., & Thomason, A. R. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1428-2 · Cited by 76
Raskob, G. E., Ageno, W., Cohen, A. T., Brekelmans, M. P. A., GROSSO, M. A., Segers, A. E. M., Meyer, G., Verhamme, P. B., Wells, P. S., Lin, M., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)00023-5 · Cited by 68
Cohen, A. T., Hamilton, M., Bird, A., Mitchell, S. A., Li, S., Horblyuk, R. V., & Batson, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160064 · Cited by 74
Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome
Noël, N., Dutasta, F., Costedoat-Chalumeau, N., Bienvenu, B., Mariette, X., Geffray, L., Sène, D., Chaidi, R. B., Michot, J., Fain, O., et al. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2015.03.007 · Cited by 73
New oral anticoagulant agents – general features and outcomes in subsets of patients
Schulman, S. (2014) · Thrombosis and Haemostasis · doi:10.1160/th13-09-0803 · Cited by 69
Self-citationPractical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants
Pollack, C. V., & Weitz, J. I. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-03-0222 · Cited by 70
“Low rates of bleeding were also seen in the extended treatment studies where, compared with placebo, dabigatran, rivaroxaban and apixaban reduced the risk of recurrent VTE by 80–92 % without any significant increase in major bleeding (▶ Table 2) (22, 24, 25).”
BackgroundResultDufrost, V., Wahl, D. G., & Zuily, S. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102711 · Cited by 71
Diagnosis and management of iliofemoral deep vein thrombosis: clinical practice guideline
Liu, D. M., Peterson, E. A., Dooner, J., Baerlocher, M. O., Zypchen, L. N., Gagnon, J., Delorme, M., Sing, C. K., Wong, J., Guzman, R., et al. (2015) · Canadian Medical Association Journal · doi:10.1503/cmaj.141614 · Cited by 68
Skaistis, J., & Tagami, T. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137444 · Cited by 64
Statins Effects on Blood Clotting: A Review
Siniscalchi, C., Basaglia, M., Riva, M. A., Meschi, M., Meschi, T., Castaldo, G., & Micco, P. D. (2023) · Cells · doi:10.3390/cells12232719 · Cited by 62
“Low molecular weight heparin (LMWH), unfractionated heparin (UFH), vitamin K antagonists (VKA) and direct oral anticoagulants (DOACs) are the gold standard of treatment for VTE [3,4], despite their related risk of bleeding [3,4].”
BackgroundGu, Z., Zhou, L., Shen, L., Zhang, C., Pu, J., Lin, H., & Liu, X.-Y. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00348 · Cited by 64
“Finally, 12 eligible RCTs were included in the analyses (Figure 1 and Table S1) (Connolly et al., 2009; Schulman et al., 2009, 2013, 2014; EINSTEIN Investigators et al., 2010; Granger et al., 2011; Patel et al., 2011; EINSTEIN–PE Investigators et al., 2012; Hori et al., 2012; Agnelli et al., 2013;…”
BackgroundHuisman, M. V., Ferreira, M., Feuring, M., Fraessdorf, M., & Klok, F. A. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14226 · Cited by 65
Extended treatment of venous thromboembolism: a systematic review and network meta-analysis
Wang, K.-L., van Es, N., Cameron, C. G., Castellucci, L. A., Buller, H. R., & Carrier, M. (2018) · Heart · doi:10.1136/heartjnl-2018-313617 · Cited by 64
Anticoagulation for the initial treatment of venous thromboembolism in people with cancer
Hakoum, M. B., Kahale, L. A., Tsolakian, I. G., Matar, C. F., Yosuico, V. E. D., Terrenato, I., Sperati, F., Barba, M., Schünemann, H. J., & Akl, E. A. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006649.pub7 · Cited by 65
Apixaban for Extended Treatment of Provoked Venous Thromboembolism
Piazza, G., Bikdeli, B., Pandey, A. K., Krishnathasan, D., Khairani, C. D., Bejjani, A., Morrison, R. H., Hogan, H., Rashedi, S., Pfeferman, M. B., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2509426 · Cited by 65
Self-citationLoke, Y. K., Pradhan, S., Yeong, J. K.-Y., & Kwok, C. S. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12376 · Cited by 63
Achilles, A., Mohring, A., Dannenberg, L., Grandoch, M., Hohlfeld, T., Fischer, J., Levkau, B., Kelm, M., Zeus, T., & Polzin, A. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13595 · Cited by 61
“[1, 2] Additionally, dabigatran is currently the only DOAC with an approved specific antidote that reverses its anticoagulatory effects within minutes.”
Gómez-Outes, A., Lecumberri, R., Suárez-Gea, M. L., Terleira-Fernández, A.-I., Monreal, M., & Vargas-Castrillón, E. (2015) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248415575154 · Cited by 57
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism
Robertson, L., Kesteven, P. J., & McCaslin, J. E. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010957.pub2 · Cited by 62
Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review
Bikdeli, B., Tajrishi, F. Z., Sadeghipour, P., Talasaz, A. H., Fanikos, J. R., Lippi, G., Siegal, D. M., Eikelboom, J. W., Monréal, M., Jiménez, D., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.1292 · Cited by 61
Self-citationMearns, E. S., Kohn, C. G., Song, J.-S., Hawthorne, J., Meng, J., White, C. M., Raut, M. K., Schein, J. R., & Coleman, C. I. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.05.035 · Cited by 61
“Schulman 2013 [55] RCT VTE 1426 54 100% Multinational NR N 16 (1901) W van Bladel 2010⁎ [56] RD/AC clinic PE 86 58 0% Europe Linear N 3 (22) A van Dongen 2005 [57] PD/Community DVT 244 62 0% Europe Linear N 3 (61) NR van Gogh 2007 [58] RCT DVT PE 1452 1120 59 62 0% Europe Linear N 5 (605) 5 (467) W,A”
BackgroundAntithrombotic Management of Venous Thromboembolism
Renner, E., & Barnes, G. D. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.07.070 · Cited by 59
Khan, F. A., Tritschler, T., Kimpton, M., Wells, P. S., Kearon, C., Weitz, J. I., Buller, H. R., Raskob, G. E., Ageno, W., Couturaud, F., et al. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15491 · Cited by 58
Self-citationBurr, N. E., Lummis, K., Sood, R., Kane, J. S., & Subramanian, V. (2016) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(16)30162-5 · Cited by 60
Xu, Y., & Siegal, D. M. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15466 · Cited by 65
Weinberg, E. M., Palecki, J., & Reddy, K. R. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1679934 · Cited by 56
Marik, P. E., & Cavallazzi, R. (2015) · PLOS ONE · doi:10.1371/journal.pone.0143252 · Cited by 53
Bauersachs, R. M., Beyer‐Westendorf, J., Bounameaux, H., Brighton, T., Cohen, A. T., Davidson, B. L., Holberg, G., Kakkar, A. K., Lensing, A. W. A., Prins, M. H., et al. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-02-0131 · Cited by 55
“Dabigatran has also been compared with warfarin for extended secondary prevention and was shown to have similar efficacy, but a reduced risk of major bleeding (9).”
BackgroundSelf-citationAspirin for prevention and treatment of venous thromboembolism
Becattini, C., & Agnelli, G. (2014) · Blood Reviews · doi:10.1016/j.blre.2014.03.003 · Cited by 53
“The efficacy and safety of dabigatran in the extended treatment of venous thromboembolism have been explored in two studies (Table 3) [53].”
BackgroundMethodInfluentialHarder, S. (2014) · Thrombosis Journal · doi:10.1186/1477-9560-12-22 · Cited by 54
“Dabigatran is unique in this setting in that it was compared both against placebo (RESONATE) and against warfarin (RE-MEDY) for 6 months of extended treatment in patients who had already received at least 3 months’ anticoagulation [11].”
BackgroundWu, T., Lv, C., Wu, L., Chen, W., Lv, M., Jiang, S., & Zhang, J. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10448-2 · Cited by 54
Brunetti, N. D., Gesuete, E., Gennaro, L. D., Correale, M., Caldarola, P., Gaglione, A., & Biase, M. D. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.12.168 · Cited by 54
Changes in the landscape of anticoagulation: a focus on direct oral anticoagulants
Ageno, W., Caramelli, B., Donadini, M. P., Girardi, L., & Riva, N. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00281-3 · Cited by 56
Sardar, P., Chatterjee, S., & Mukherjee, D. (2013) · Drugs · doi:10.1007/s40265-013-0082-7 · Cited by 50
“Only, the, RE-MEDY trial directly compared a new oral anticoagulant (dabigatran) with warfarin for this indication and the efficacy result (recurrent venous thromboembolism) just marginally met the prespecified noninferiority boundary [11].”
BackgroundInfluentialRadadiya, D. K., Devani, K., Brahmbhatt, B. S., & Reddy, C. M. (2021) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002035 · Cited by 55
Liew, A., Eikelboom, J. W., O'Donnell, M. J., & Hart, R. G. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2013.04.013 · Cited by 58
Management of venous thromboembolism: an update
Piran, S., & Schulman, S. (2016) · Thrombosis Journal · doi:10.1186/s12959-016-0107-z · Cited by 53
“All trials showed marked superiority of the DOACs over placebo for the prevention of recurrent VTE without significant increase in major bleeding [17,50, 51].”
BackgroundMethodResultInfluentialSelf-citationItalian intersociety consensus on DOAC use in internal medicine
SIMI (Italian Society of Internal Medicine), Prisco, D., SISET (Italian Society for the Study of Haemostasis and Thrombosis), Ageno, W., Becattini, C., D’Angelo, A., Davì, G., CRISTOFARO, R. D., Dentali, F., Minno, G. D., et al. (2017) · Internal and Emergency Medicine · doi:10.1007/s11739-017-1628-6 · Cited by 49
Palareti, G., Antonucci, E., Mastroiacovo, D., Ageno, W., Pengo, V., Poli, D., Testa, S., Tosetto, A., & Prandoni, P. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14253 · Cited by 52
Huang, H., Liu, P. P., Hsu, J., Lin, S., Peng, C. C., Wang, J., & Loh, C. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz952 · Cited by 52
Morimoto, T., Crawford, B., Wada, K., & Ueda, S. (2015) · Journal of Cardiology · doi:10.1016/j.jjcc.2015.05.018 · Cited by 52
Fang, M. C., Reynolds, K., Fan, D., Prasad, P. A., Sung, S. H., Portugal, C., Garcia, E. A., & Go, A. S. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.28033 · Cited by 49
Wolfe, Z., Khan, S. U., Nasir, F., Subramanian, C. R., & Lash, B. W. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14131 · Cited by 51
Peri-procedural management of patients taking oral anticoagulants
Daniels, P. R. (2015) · BMJ · doi:10.1136/bmj.h2391 · Cited by 47
Anticoagulation for perioperative thromboprophylaxis in people with cancer
Matar, C. F., Kahale, L. A., Hakoum, M. B., Tsolakian, I. G., Etxeandia‐Ikobaltzeta, I., Yosuico, V. E. D., Terrenato, I., Sperati, F., Barba, M., Schünemann, H. J., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009447.pub3 · Cited by 47
Sex matters: Practice 5P's when treating young women with venous thromboembolism
Bistervels, I. M., Scheres, L. J. J., Hamulyák, E. N., & Middeldorp, S. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14549 · Cited by 48
Evidence Gaps in the Era of Non–Vitamin K Oral Anticoagulants
Aronis, K. N., & Hylek, E. M. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007338 · Cited by 48
Meta-Analysis of Randomized Controlled Trials on the Risk of Bleeding With Dabigatran
Bloom, B. J., Filion, K. B., Atallah, R., & Eisenberg, M. J. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.11.049 · Cited by 44
Ageno, W., & Beyer‐Westendorf, J. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-06-0484 · Cited by 46
“The overall number of adverse events did not differ significantly between treatment groups, yet the number of acute coronary syndrome events was significantly higher with dabigatran compared with warfarin (67).”
BackgroundInfluentialBertoletti, L., Ollier, É., Duvillard, C., Delavenne, X., Beyens, M., Magalhaes, É. D., Bellet, F., Basset, T., Mismetti, P., & Laporte, S. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.06.023 · Cited by 47
Self-citationSindet-Pedersen, C., Pallisgaard, J. L., Staerk, L., Berger, J. S., Lamberts, M., Torp-Pedersen, C., Gislason, G. H., & Olesen, J. B. (2017) · Scientific Reports · doi:10.1038/s41598-017-03596-x · Cited by 44
A Practical Review of the Emerging Direct Anticoagulants, Laboratory Monitoring, and Reversal Agents
Joppa, S., Salciccioli, J. D., Adamski, J., Patel, S. I., Wysokiński, W. E., McBane, R. D., Al‐Saffar, F., Esser, H., & Shamoun, F. E. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7020029 · Cited by 49
“The Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long-Term Prevention of Recurrent Symptomatic VTE (RE-SONATE) and Secondary Prevention of Venous Thrombo Embolism (VTE) (RE-MEDY) trials [39] compared dabigatran versus warfarin treatment of long-term VTE treatment, finding that dabigatran was…”
BackgroundCouturaud, F., Pernod, G., Presles, É., Duhamel, E., Jégo, P., Provost, K., Pan‐Petesch, B., Sollier, C. B. D., Tromeur, C., Hoffmann, C., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.210971 · Cited by 47
Self-citationUse of direct oral anticoagulants in daily practice.
Almarshad, F., Alaklabi, A. A., Bakhsh, E., Pathan, A. R., & Almegren, M. (2018) · Europe PMC (PubMed Central) · Cited by 50
Wang, X., Ma, Y., Xu, H., Li, M., Li, J., Tian, J., Wang, Q., Yan, P., Li, J., Xie, P., et al. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010956.pub3 · Cited by 52
Effective diagnosis and treatment of pulmonary embolism: Improving patient outcomes
Meyer, G. (2014) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2014.05.006 · Cited by 48
Sobieraj, D. M., Coleman, C. I., Pasupuleti, V., Deshpande, A., Kaw, R., & Hernandez, A. V. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.02.032 · Cited by 42
“[13] VKAs were compared to either placebo or control (i.”
BackgroundAnticoagulant use in older persons at risk for falls: therapeutic dilemmas—a clinical review
Mitchell, A., Elmasry, Y. E. T., van Poelgeest, E. P., & Welsh, T. J. (2023) · European Geriatric Medicine · doi:10.1007/s41999-023-00811-z · Cited by 43
“1 3 for extended VTE treatment and anticoagulant dosing has largely been derived from randomised controlled trials which under-represented older people, only 15% of those included in the apixaban trial were aged ≥ 75 years [79], and the average ages of participants in the rivaroxaban and dabigatran trials were 58 and…”
MethodVenous Thromboembolism: Review of Clinical Challenges, Biology, Assessment, Treatment, and Modeling
Watson, C. T., Saaid, H., Vedula, V., Cardenas, J. C., Henke, P. K., Nicoud, F., Xu, X. Y., Hunt, B. J., & Manning, K. B. (2023) · Annals of Biomedical Engineering · doi:10.1007/s10439-023-03390-z · Cited by 46
“However, their use is not recommended for patients with renal or hepatic failure due to reduced clearance rates [73, 88–91].”
Wu, C. M., Alotaibi, G., AlSaleh, K. A., Linkins, L., & McMurtry, M. S. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.10.033 · Cited by 43
“Three of the studies compared a DOAC (dabigatran, apixaban, and rivaroxaban) to placebo [12,28, 29], and one study, the RE-MEDY trial, used an active comparator (dabigatran vs.”
MethodResultInfluentialNew anticoagulants for the treatment of venous thromboembolism
Fernandes, C. J. C. D. S., Alves, J. L., Gavilanes, F., Prada, L. F., Morinaga, L. T. K., & Souza, R. (2016) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37562016042020068 · Cited by 70
“There were no differences in the rate of acute coronary syndrome events.(20)”
BackgroundHow I treat recurrent deep-vein thrombosis
Kyrle, P. A. (2015) · Blood · doi:10.1182/blood-2015-09-671297 · Cited by 42
Kumano, O., Akatsuchi, K., & Amiral, J. (2021) · Biomedicines · doi:10.3390/biomedicines9030264 · Cited by 45
Gómez‐Outes, A., Suárez‐Gea, M. L., Lecumberri, R., Terleira‐Fernández, A., & Vargas, E. (2014) · Vascular Health and Risk Management · doi:10.2147/vhrm.s50543 · Cited by 43
Management of antithrombotic agents in patients undergoing flexible bronchoscopy
Abuqayyas, S., Raju, S., Bartholomew, J. R., Hweij, R. A., & Mehta, A. C. (2017) · European Respiratory Review · doi:10.1183/16000617.0001-2017 · Cited by 40
Drug interactions with new oral anticoagulants in elderly patients
Stöllberger, C. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1370369 · Cited by 47
“[1] Dabi RE-LY Man AF 18,113 40% 71 24 [2] Dabi RE-COVER I Man VTE 2,564 NR 54 6 [3] Dabi RE-COVER II Man VTE 2,589 NR 55 6 [4] Dabi RE-MEDY Man VTE 4,219 NR 55 16 [5] Apix ARISTOTLE Man AF 18,201 31% 70 22 [6] Apix AMPLIFY Man VTE 5,395 NR 57 6 [7] Riva ROCKET AF Man AF 14,264 38% 73 20 [8] Riva EINSTEIN DVT Man VTE…”
How can we reverse bleeding in patients on direct oral anticoagulants?
Crowther, M. A., & Cuker, A. C. (2018) · Kardiologia Polska · doi:10.5603/kp.a2018.0197 · Cited by 43
Guo, W., Chen, X., Tian, X., & Li, L. (2019) · Clinical Epidemiology · doi:10.2147/clep.s219335 · Cited by 41
“One study was the report of two trials (RE-MEDYand RE-SONATE trial).(40) The network plot of the comparisons is given in Figure 2.”
BackgroundAlhousani, M. M., Malik, S. U., Abu-Hashyeh, A., Poznanski, N. J., Al-Hasan, S., Roth, D. F., Alsharedi, M. F., & Mustafa, B. O. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.11.036 · Cited by 40
Vitamin K Antagonists and Risk of Subdural Hematoma: Meta-Analysis of Randomized Clinical Trials
Connolly, B. J., Pearce, L. A., & Hart, R. G. (2014) · Stroke · doi:10.1161/strokeaha.114.005430 · Cited by 43
Oral Anticoagulation and Risk of Adverse Clinical Outcomes in Venous Thromboembolism
Bea, S., Iyer, G. S., Kim, D., Lin, K. J., Zhang, Y., Zakoul, H., Tesfaye, H., & Bykov, K. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.1109 · Cited by 39
Potential antidotes for reversal of old and new oral anticoagulants
Suryanarayan, D., & Schulman, S. (2014) · Thrombosis Research · doi:10.1016/s0049-3848(14)50026-6 · Cited by 42
“Dabigatran demonstrated similar efficacy as enoxaparin for prophylaxis after hip [10,11] and knee arthroplasty [12] and was as effective as warfarin for acute management [13] and extended maintenance therapy for venous thromboembolism (VTE) [14].”
BackgroundSelf-citationSun, M. T., Wood, M. K., Chan, W. O., Selva, D. N., Sanders, P., Casson, R. J., & Wong, C. X. J. (2017) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2017.2199 · Cited by 46
Management of Venous Thromboembolisms: Part I. The Consensus for Deep Vein Thrombosis.
Wang, K.-L., Chu, P. H., Lee, C., Pai, P. Y., Lin, P.-Y., Shyu, K. G., Chang, W., Chiu, K., Huang, C.-L., Lee, C. Y., et al. (2016) · Europe PMC (PubMed Central) · doi:10.6515/acs20151228a · Cited by 49
Anticoagulantes orales directos: puesta al día
Franco‐Moreno, A., Díaz, R. M. M., & Navarro, M. J. G. (2017) · Medicina Clínica · doi:10.1016/j.medcli.2017.11.042 · Cited by 39
Bradbury, C. A., Fletcher, K., Sun, Y., Heneghan, C. J., Gardiner, C., Roalfe, A. K., Hardy, P., McCahon, D., Heritage, G., Shackleford, H., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.16275 · Cited by 44
Jacquemin, M. G., Toelen, J., Schoeters, J., Horenbeeck, I. V., Vanlinthout, I., Debasse, M., Peetermans, M., Vanassche, T., Peerlinck, K., van Ryn, J., et al. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13138 · Cited by 38
Cohen, A. T., Imfeld, S., & Rider, T. (2014) · Advances in Therapy · doi:10.1007/s12325-014-0119-7 · Cited by 40
“The RE-MEDY study (Tables 3, 5) compared dabigatran with warfarin in a 6- to 36-month extended treatment period after 3–12 months of initial VTE therapy [24].”
BackgroundMethodResultInfluentialReiffel, J. A., Weitz, J. I., Reilly, P. A., Kaminskas, E., Sarich, T. C., Sager, P. T., & Seltzer, J. H. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.04.010 · Cited by 38
“For the latter it could: (1) use historic data to set some risk thresholds for adverse outcomes and compare these to actual rates in the Mini-Sentinel Distributed Database; (2) provide reassurance that incidence rates of adverse outcomes are below a specified and meaningful level; (3) to compare reversal treatment for…”
BackgroundMethodInfluentialLong-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE
Wells, P. S., Prins, M. H., Levitan, B. S., Beyer‐Westendorf, J., Brighton, T., Bounameaux, H., Cohen, A. T., Davidson, B. L., Prandoni, P., Raskob, G. E., et al. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.05.023 · Cited by 40
Direct oral anticoagulants and venous thromboembolism
Franchini, M., & Mannucci, P. M. (2016) · European Respiratory Review · doi:10.1183/16000617.0025-2016 · Cited by 40
Breadth of complications of long-term oral anticoagulant care
Ageno, W., & Donadini, M. P. (2018) · Hematology · doi:10.1182/asheducation-2018.1.432 · Cited by 40
“In the randomized controlled trials, 1 of 5 major bleeding events that occurred in patients treated with rivaroxaban 20 mg in the EINSTEIN CHOICE study was fatal, whereas no fatal events were reported with the 10-mg dose of rivaroxaban in the same study, or with edoxaban or dabigatran.(12,13,16) In the Dresden registr…”
BackgroundRivaroxaban and the EINSTEIN clinical trial programme
Cohen, A. T., & Bauersachs, R. M. (2019) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000800 · Cited by 43
Extended Anticoagulation for VTE
Mai, V., Guay, C.-A., Perreault, L., Bonnet, S., Bertoletti, L., Lacasse, Y., Mainbourg, S., Lega, J., & Provencher, S. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.02.402 · Cited by 38
Long-term clinical course of acute pulmonary embolism
den Exter, P. L., van der Hulle, T., Lankeit, M., Huisman, M. V., & Klok, F. A. (2013) · Blood Reviews · doi:10.1016/j.blre.2013.06.003 · Cited by 42
“The RE-MEDY study was a non-inferiority study comparing extended treatment with the direct thrombin inhibitor dabigatran 150 mg twice daily to warfarin after initial anticoagulation treatment for at least three months [62].”
BackgroundMethodCancer-associated thrombosis: investigating the role of new oral anticoagulants
Franchini, M., Bonfanti, C., & Lippi, G. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.02.024 · Cited by 38
“In the randomized, double blind superiority RE-MEDY trial [24], extended treatment with dabigatran (150 mg twice daily) was compared to warfarin for the long-term management of VTE and enrolled patients with acute VTE that had successfully been treated with anticoagulants for a period of 3 to 6 months.”
BackgroundMethodInfluentialWho, when, and how to reverse non-vitamin K oral anticoagulants
Aronis, K. N., & Hylek, E. M. (2015) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1297-0 · Cited by 39
Halton, J. M., Albisetti, M., Biss, B., Bomgaars, L. R., Brueckmann, M., Gropper, S., Harper, R., Huang, F., Luciani, M., Maas, H. J., et al. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13847 · Cited by 37
Панченко, Е. П., Balahonova, T. V., Danilov, N. M., Komarov, A. L., Станиславовна, К. Е., Saidova, M. A., Shakhmatova, O. O., & Yavelov, I. S. (2021) · Eurasian heart journal · doi:10.38109/2225-1685-2021-1-44-77 · Cited by 39
Metadata
- Authors
- Schulman, S., Kearon, C., Kakkar, A. K., Schellong, S., Eriksson, H., Baanstra, D., Kvamme, A. M., Friedman, J., Mismetti, P., & Goldhaber, S. Z.
- Affiliations
- Karolinska University Hospital (SE)
- Thrombosis and Atherosclerosis Research Institute (CA)
- Thrombosis Research Institute (GB)
- Krankenhaus Dresden-Friedrichstadt (DE)
- Sahlgrenska University Hospital (SE)
- Boehringer Ingelheim (Netherlands) (NL)
- Boehringer Ingelheim (Norway) (NO)
- Boehringer Ingelheim (United States) (US)
- Centre Hospitalier Universitaire de Saint-Étienne (FR)
- Brigham and Women's Hospital (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-02-21
- Volume
- 368
- Issue
- 8
- Pages
- 709-718
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2112378432
- Cited by
- 983
- References
- 25
- Citations by year
- 2026: 22 · 2025: 26 · 2024: 42 · 2023: 32 · 2022: 38 · 2021: 65 · 2020: 62 · 2019: 67 · 2018: 90 · 2017: 71 · 2016: 103 · 2015: 124 · 2014: 141 · 2013: 97
- FWCI
- 135.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- dabigatran, warfarin, venous thromboembolism, long-term anticoagulation, recurrent venous thromboembolism, major bleeding, acute coronary syndrome, direct oral anticoagulants, non-inferiority, thromboprophylaxis, thrombolysis, anticoagulant reversal
- MeSH terms
- Dabigatran, Adolescent, Adult, Aged, Aged, 80 and over, Benzimidazoles, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Recurrence, Risk, Warfarin, beta-Alanine, International Normalized Ratio, Venous Thromboembolism, Young Adult, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.